Media coverage about Celyad (NASDAQ:CYAD) has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celyad earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.7796570365371 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Celyad (CYAD) opened at $45.44 on Friday. Celyad has a 52 week low of $19.00 and a 52 week high of $64.75.
A number of equities analysts have commented on the company. Piper Jaffray Companies restated an “overweight” rating and issued a $74.00 target price on shares of Celyad in a research note on Monday, October 9th. ValuEngine downgraded Celyad from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
Receive News & Ratings for Celyad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad and related companies with MarketBeat.com's FREE daily email newsletter.